ACE-inhibitor use and the long-term risk of renal failure in diabetes

Kidney International

Volumn 69, Issue 5, 2006, Pages 913-919

  Suissa, S ^a   Hutchinson, T ^a   Brophy, J M ^a   Kezouh, A ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

ACE inhibitors; Cohort studies; Diabetes mellitus; Dialysis; Hypertension; Nephropathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; INSULIN; LOOP DIURETIC AGENT; METHYLDOPA; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANADA; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 33644530729     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ki.5000159     Document Type: Article

References (46)

1. Gilman AG, Goodman LS, Gilman A (eds). The Pharmacological Basis of Therapeutics, 6th/7th edn. MacMillan Publishing Co.: New York, 1980/1985.
2. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: 1988 report. Arch Intern Med 1988; 148: 1023-1038.
3. Isselbacher KJ, Harrison TR, Wilson J, Fauci AS, Braunwald E, Martin JB, Kasper DI (eds). Harrison's Principles of Internal Medicine, 13th edn. McGraw Hill: New York, 1994.
4. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
5. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
6. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-677.
7. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418.
8. Friedman EA. Diabetic nephropathy: strategies in prevention and management. Kidney Int 1982; 21: 780-791.
9. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.
10. Jones CA, Kroloewski AS, Rogus J et al. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005; 67: 1684-1691.
11. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Int Med 1993; 118: 129-138.
12. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
13. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
14. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of hope study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
15. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
16. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patient with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
18. Parving H-H, Hommel E, Nielsen MD, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependant diabetics with nephropathy. BMJ 1989; 299: 533-536.
19. Mathiesen ER, Hommel E, Giese J, Parving H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependant diabetic patients with microalbuminuria. BMJ 1991; 303: 81-87.
20. Cook J, Daneman D, Spino M et al. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependant diabetes mellitus. J Pediatr 1990; 117: 39-45.
21. Weigman TB, Herron KG, Chonko AM et al. Effect of angiotensin-converting enzyme inhibition on renal function and albuminuria in normotensive type I diabetic patients. Diabetes 1992; 41: 62-67.
22. Hommel E, Parving H-H, Mathiesen E et al. Effect of captopril on kidney function in insulin-dependant diabetic patients with nephropathy. BMJ 1986; 293: 467-470.
23. Bjorck S, Mulec H, Johnsen SA et al. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ 1990; 300: 904-907.
24. Ravid M, Savin H, Jutrin I et al. Long -term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 1993; 118: 577-581.
25. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Int Med 1993; 153: 973-980.
26. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Int Med 1990; 112: 707-708.
27. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210-216.
28. Marre M, Chatellier G, Leblanc H et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-1095.
29. Bianchi S, Bigazzi R, Baldari G et al. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with end-stage renal insufficiency: a 1-year follow-up. Am J Nephrol 1991; 11: 131-137.
30. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. Arch Int Med 1993; 153: 2426-2435.
31. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med 1993; 118: 643-644.
32. Sawicki PT, Muhlhauser I, Baba T, Berger M. Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia 1990; 33: 121-124.
33. Rett K. Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Diabetologia 1991; 34: 137.
34. Sawicki PT, Muhlhauser I, Berger M. Do angiotensin converting enzyme inhibitors represent a progress in hypertension care in diabetes mellitus? Response from the authors. Diabetologia 1991; 34: 138.
35. Fournier A, Lalau JD. The effect of angiotensin converting enzymes inhibition on diabetic nephropathy. N Engl J Med 1994; 330: 937.
36. Lopez A, Marantz PR. The effect of angiotensin converting enzymes inhibition on diabetic nephropathy. N Engl J Med 1994; 330: 937.
37. Parving H-H. The effect of angiotensin converting enzymes inhibition on diabetic nephropathy. N Engl J Med 1994; 330: 937-938.
38. Sambhi MP, Gavras H, Robertson JIS, Smith WM. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension - do we need more clinical trials? West J Med 1993; 158: 286-294.
39. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993; 329: 2029-2032.
40. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267-271.
41. Zatz R, Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
42. Remuzzi G, Ruggenenti P. Slowing the progression of diabetic nephropathy. N Engl J Med 1993; 329: 1496-1497.
43. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive hear failure. Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
44. West R. Saskatchewan health data bases: a developing resource. Am J Prev Med 1987; 4(Suppl 2): 25-27.
45. Strand LM, West R. Health databases in Saskatchewan. In: Strom B (ed). Pharmacoepidemiology: The Sciences of Postmarketing Drug Surveillance. Churchill Livingstone: New York, 1989 pp 189-200.
46. Suissa S. Novel approaches to pharmacoepidemiological study design and statistical analysis (Chapter 44). In: Strom B (ed). Pharmacoepidemiology, 3rd edn. John Wiley & Sons: New York, 2000.